赛诺菲(SNY) - 2023 Q3 - Quarterly Report

Press Release Specialty Care growth, strong launch uptake of Beyfortus and ALTUVIIIO drive solid Q3 results ® ® Paris, October 27, 2023 Q3 2023 sales growth of 3.2% at CER and business EPS decrease of 2.1% at CER (1) Key R&D milestones and regulatory achievements in Q3 Progress on Corporate Social Responsibility strategy in Q3 • Sanofi Global Health Unit: first deliveries of cardio-metabolic products under the Impact brand to the Republic of Djibouti and to global non-governmental organizations Full-year 20 ...